Updated

The Food and Drug Administration warned that it has found evidence of a potential increased risk of a rare eye condition linked to GLP-1 drugs used for weight management and diabetes, including Wegovy and Zepbound. The agency's finding concerns a potential increased risk rather than a confirmed causal link. The warning covers a widely used class of drugs, and the report did not specify how many patients might be affected.